A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

Trial ID #	NCT01610206
Phase	II
Drug Class	Angiogenesis Inhibitors: Multi-targeted RTK
Drug Name	Pazopanib
Alternate Drug Names	Votrient
Drugs in Trial	Pazopanib, Gemcitabine
Eligible Participant	Recurrent or persistent ovarian cancer
Patients Enrolled	148
Therapy Setting	Recurrence
Study Design	Open-Label, Randomized
Endpoints	ORR, DCR, PFS, evaluated per RECIST
Efficacy	Paz+Gem vs Gem: ORR: 20 vs 11%, p=0.02 DCR: 80 vs 60%, p<0.001 PFS: 5.3 vs 2.9 months Exploratory analysis: Pt-R patients: Paz+Gem vs Gem: PFS: 5.32 vs 2.33 months, p<0.001
Clinically Significant Adverse Events	Serious AE: Grade 3-4 AE:
Conclusion	The addition of pazopanib to gemcitabine enhances the anti-tumor activity, in particular in patients with Pt-R disease
Reference	Duska LR et al. A Randomized Phase II Evaluation of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma. Gynecol Oncol (2020) 157(3):585-592 https://pubmed.ncbi.nlm.nih.gov/32247603/